BiotechTube

Tremelimumab + Olaparib

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Peritoneal Carcinoma

Conditions

Primary Peritoneal Carcinoma

Trial Timeline

Jan 8, 2016 → Mar 5, 2020

NCT ID
NCT02485990

About Tremelimumab + Olaparib

Tremelimumab + Olaparib is a phase 1 stage product being developed by AstraZeneca for Primary Peritoneal Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02485990. Target conditions include Primary Peritoneal Carcinoma.

What happened to similar drugs?

20 of 20 similar drugs in Primary Peritoneal Carcinoma were approved

Approved (20) Terminated (6) Active (0)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Duloxetine + PlaceboEli LillyApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02485990Phase 1Terminated

Competing Products

20 competing products in Primary Peritoneal Carcinoma

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31